IP50-11: Comparative Outcomes of Gemcitabine Alone versus Gemcitabine + Docetaxel in Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

IP50-11: Comparative Outcomes of Gemcitabine Alone versus Gemcitabine + Docetaxel in Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Sunday, May 17, 2026 7:00 AM to 9:00 AM · 1 hr. 59 min. (America/New_York)

146A

Abstract

Speakers

Ao Zhang

ResidentCleveland Clinic

Sessions

IP50: Bladder Cancer: Non-invasive IV

Sunday, May 17, 2026 7:00 AM to 9:00 AM

Christopher Anderson · Columbia University Medical Center

William Tabayoyong · Department of Urology

Mary Westerman · Department of Urology, University of North Carolina

Registered attendees

Scott Flanders

VP of Medical AffairsImmunityBio, Inc.

Log in

See all the content and easy-to-use features by logging in or registering!